Epistem, the UK biotechnology and personalised medicine company, announced that it has been reappointed for up to 5 years as a subcontractor to the U.S. National Institute of Health (NIH). Epistem will provide preclinical testing services to the Radiation/Nuclear Medical Countermeasure Product Development Support Services Contract, which has been awarded to the University of Maryland School of Medicine (UMSOM) in Baltimore. The UMSOM programme aims to identify and develop new treatments for use in the event of a nuclear or radiological incident.
Epistem's role as a member of the research consortium is to provide specialized gastrointestinal models to assess the efficacy and mode of action of new drugs entering the programme. In Epistem’s previous subcontract, which began in 2006, the company’s role was to refine drug screening methods, further characterise the biology of radiation damage in the gastrointestinal tract and assess several new drug candidates. Epistem received approximately $3.5 million over the course of the previous contract. Epistem is the only research facility outside of North America within the consortium.
About the Author
LCF Research
0 comments
